Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Description

The introduction of anti-tumour necrosis factor (TNF) antibodies into the treatment of patients with IBD about fifteen years ago has dramatically improved the quality of life for patients with severe Crohn's disease and ulcerative colitis. But despite the fact this therapeutic approach has been around for quite some time, there has been no comprehensive overview to date. The book at hand aims to amend this shortcoming, presenting for the first time a thorough overview on TNF action, mechanisms of anti-TNF therapy, treatment strategies, side effects, monitoring, biosimilars and related issues. Including state-of-the-art information and research results, this publication will be a valuable source of information and guide clinicians to the optimal treatment decision, improving the quality of life of patients with inflammatory bowel disease. Moreover, rheumatologists or even dermatologists might also find this book of interest.

Informations

• Publié par: S. Karger AG
• Date de parution: 09 juillet 2015
• Nombre de lectures: 0
• EAN13: 9783318054743
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Frontiers of Gastrointestinal Research
Vol. 34
Series Editor
Choitsu Sakamoto Tokyo
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Volume Editors
Gerhard Rogler Zurich
Hans Herfarth Chapel Hill, N.C.
Toshifumi Hibi Tokyo
Ole Haagen Nielsen Copenhagen
26 figures, 17 in color, and 15 tables, 2015
Frontiers of Gastrointestinal Research
______________________ Gerhard Rogler Klinik für Gastroenterologie und Hepatologie Universitäts Spital Zürich CH-8091 Zurich (Switzerland)
______________________ Hans Herfarth Division of Gastroenterology and Hepatology UNC School of Medicine Chapel Hill, NC 27599-7080 (USA)
______________________ Toshifumi Hibi Center for Advanced IBD Research and Treatment Kitasato Institute Hospital Tokyo, Minato-ku 108-8642 (Japan)
______________________ Ole Haagen Nielsen Dept. of Gastroenterology, Medical Section Herlev Hospital University of Copenhagen (Denmark)
Library of Congress Cataloging-in-Publication Data
Anti-tumor necrosis factor therapy in inflammatory bowel disease/volume editors, Gerhard Rogler, Toshifumi Hibi, Hans Herfarth, Ole Haagen Nielsen.
p.; cm. -- (Frontiers of gastrointestinal research, ISSN 0302-0665 ; vol. 34)
Includes bibliographical references and indexes.
ISBN 978-3-318-05473-6 (hard cover: alk. paper) -- ISBN 978-3-318-05474-3 (electronic version)
I. Rogler, G. (Gerhard), editor. II. Hibi, Toshifumi, 1947-, editor. III. Herfarth, H., editor. IV. Nielsen, Ole Haagen, editor. V. Series: Frontiers of gastrointestinal research ; v. 34. 0302-0665
[DNLM: 1. Inflammatory Bowel Diseases--therapy. 2. Tumor Necrosis Factors. W1 FR946E v.34 2015 / WI 420]
RC862.I53
616.3'44--dc23
2015017502
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents ® and Index Medicus.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2015 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Germany on acid-free and non-aging paper (ISO 9706) by Kraft Druck GmbH, Ettlingen
ISSN 0302-0665
e-ISSN 1622-3754
ISBN 978-3-318-05473-6
e-ISBN 978-3-318-05474-3
Contents
Preface
Rogler, G. (Zurich); Herfarth, H. (Chapel Hill, N.C.); Hibi, T. (Tokyo); Nielsen, O.H. (Copenhagen)
Physiological Role of TNF in Mucosal Immunology
The Effect of TNF-α on the Regulation of Epithelial Function in Inflammatory Bowel Disease
Tsuchiya, K. (Tokyo)
Physiological Role of TNF in Mucosal Immunology: Regulation of Macrophage/ Dendritic Cell Function
Rivollier, A. (Frederiksberg); Marsal, J. (Lund); Agace, W.W. (Frederiksberg/Lund)
Physiological Role of TNF in Mucosal Immunology: Regulation of T-Cell Function
Scharl, M. (Zurich)
Pathophysiological Role of TNF in Inflammatory Bowel Disease
Pathophysiological Role of TNF in Inflammatory Bowel Disease: TNF and Its Impact on Barrier Function
Schumann, M.; Kühnel, A. (Berlin)
Pathophysiological Role of TNF in Inflammatory Bowel Disease: TNF and Its Effect on Innate Immune Defense
Scharl, M. (Zurich)
TNF and Its Impact on Adaptive Immune Mechanisms and Chronic Inflammation
Siegmund, B. (Berlin)
Mechanism of Action of Anti-TNF Antibodies
Binding of Membrane-Bound TNF
Atreya, R.; Billmeier, U.; Rath, T.; Neumann, H.; Neurath, M.F. (Erlangen)
Apoptosis of T Cells and Monocytes
Kucharzik, T. (Hamburg)
Neutralisation of Soluble Tumor Necrosis Factor
Dreesen, E.; Gils, A. (Leuven)
General Treatment Considerations
Recommended Screening Procedures before Treatment with Anti-TNF Agents
Maaser, C. (Lueneburg)
The Risk of Formation of Neutralizing Antibodies
Clark, J.; Sakuraba, A. (Chicago, Ill.)
TNF Antagonist Trough Concentrations and Treatment Efficacy in Inflammatory Bowel Disease
Vande Casteele, N. (Leuven/La Jolla, Ca.)
Biosimilars
What Is a Biosimilar?
Neri, D. (Zurich)
Is Extrapolation of Safety and Efficacy Data Possible?
Ainsworth, M. (Herlev)
Potential Concerns and Questions
Rogler, G. (Zurich)
Side Effects of Anti-TNF Therapy
Psoriasis-Like Lesions and Skin Reactions
Herfarth, H.H.; Long, M.D.; Sayed, C. (Chapel Hill, N.C.)
The Elicitation of Rheumatic Symptoms at Vascular Sites
Geyer, M.; Müller-Ladner, U. (Bad Nauheim)
Serum Reaction, Lupus-Like Syndrome
Schnitzler, F. (Munich)
Risks of Anti-TNF Therapy
Risk of Non-Hematologic Malignancy with Anti-TNF Therapy in Inflammatory Bowel Diseases
Jain, A. (Baltimore, Md.); Herfarth, H.H.; Long, M.D. (Chapel Hill, N.C.)
Risk of Lymphoma
Nagahori, M.;Watanabe, M. (Tokyo)
Risk of Serious Infection
Naganuma, M. (Tokyo)
Risk of Post-Operative Infections with Anti-TNF Therapy
Cohen, B.L. (New York, N.Y.)
Anti-TNF Therapy in Crohn's Disease
The ‘Ideal’ Anti-TNF Patient: Indications for Anti-TNF Therapy in Crohn's Disease
Tran-Minh, M.-L.; Baudry, C.; Allez, M. (Paris)
Predictor of Treatment Response
Tanaka, H.; Motoya, S. (Hokkaido)
Step-Up or Top-Down, Combination with Immunosuppression or Not?
Barthel, C.; Stange, E.F. (Stuttgart)
Anti-TNF Therapy in Ulcerative Colitis
The ‘Ideal’ Anti-TNF Patient: Indications for Anti-TNF Therapy in Ulcerative Colitis
Hisamatsu, T. (Tokyo)
Predictors of the Treatment Response
Kim, H.J. (Seoul)
What Is the Right Dosage?
Michetti, P. (Lausanne)
Anti-TNF Therapy in Special Inflammatory Bowel Disease Situations
Fistulizing and Stricturing Crohn's Disease
Schoepfer, A.M. (Lausanne)
Postoperative Anti-TNF Therapy in the Management of Crohn's Disease
Barrie, A.; Regueiro, M. (Pittsburgh, Pa.)
Anti-TNF-α Therapy for Extraintestinal Manifestations of Inflammatory Bowel Disease
Nielsen, O.H. (Herlev); Bendtzen, K. (Copenhagen); Pedersen, J. (Herlev)
Anti-TNF Therapy in Special Situations of the Patient
Anti-TNF Alpha Agents and Breastfeeding
Al-Sum, H.; Maxwell, C.V. (Toronto)
Anti-TNF Therapy before Surgery
Vavricka, S.R.; Scharl, M.; Rogler, G. (Zurich)
When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease
When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping Treatment
Louis, E. (Liège)
Treatment Options after Anti-TNF Failure
Kobayashi, T. (Tokyo)
Author Index
Subject Index
Preface
The introduction of anti TNF antibodies into the treatment of patients with inflammatory bowel disease about fifteen years ago has dramatically changed the field of IBD therapy. This treatment option has significantly improved the quality of life for patients with severe Crohn's disease and ulcerative colitis. Extensive research has been performed analyzing the mode of action of anti TNF antibodies in vitro and in vivo, positioning this therapeutic approach in current treatment strategies and analyzing the side effects of anti-TNF strategies and various other aspects, such as monitoring of therapy. With the introduction of anti-TNF antibody biosimilars the field has become more complex and new questions have been raised.
Surprisingly so far there have been no attempt to provide a comprehensive overview on all aspects of TNF action, mechanisms of anti TNF therapy, treatment strategies, side effects, monitoring, biosimilars and many other aspects that are important with respect to anti TNF therapy. This monograph for the first time makes the effort to cover all those important aspects and answer questions that are associated with them. It is the first text book written by experts in the field that tries to bridge basic research on TNF action and on properties of the different antibodies to frequent questions regarding treatment strategies, stop options, etc. The authors have included newest results; the single chapters are focused and to the point; and the information given is helpful and pr